Código QR (código de barras bidimensional)

Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy

Background: Abemaciclib was recently approved by the European Medicines Agency in combination with adjuvant endocrine therapy (ET) for adult patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2−), node-positive early breast cancer (EBC) at high risk...

Fuld beskrivelse

Na minha lista:
Principais autores: Alison Davie, Sory Traoré, Massimo Giovannitti, Giuseppe Pompilio, Mark Lambton, Esra Cakar, Anuja Chatterjee
Format: Artigo
Sprog:Inglês
Udgivet: AboutScience Srl 2023-09-01
Serier:Global & Regional Health Technology Assessment
Fag:
Abemaciclib
Cost-effectiveness
Early breast cancer
Endocrine therapy
HER2−
HR
Online adgang:https://journals.aboutscience.eu/index.php/grhta/article/view/2561
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker